PCI Biotech Q3 2021 interim results
November 17, 2021 01:00 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 17 November 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim Q3 2021 results. Please find enclosed the report and presentation. ...
PCI Biotech: Invitation to Q3 2021 result presentation
November 09, 2021 06:50 ET
|
PCI Biotech Holding ASA
Oslo, Norway, 9 November 2021 - PCI Biotech (OSE: PCIB) invites to a presentation of the company's Q3 2021 results on Wednesday 17 November 2021 at Oslo Cancer Cluster Innovation Park. Time:...
PCI Biotech to present at the 9th International mRNA Health Conference
November 09, 2021 03:30 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 9 November 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced...
PCI Biotech: Presentation of fimaChem for bile duct cancer at IPA masterclass series
November 08, 2021 05:15 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 8 November 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that the coordinating principal investigator for the RELEASE trial, Prof. Dr. Jörg...
PCI Biotech: Employee share option scheme
September 06, 2021 12:20 ET
|
PCI Biotech Holding ASA
Oslo, 6 September 2021 In accordance with the authorisation granted and the remuneration policy adopted by the Annual General Meeting 28 May 2021, the Board of Directors of PCI Biotech...
PCI Biotech first half-year 2021 interim results
August 31, 2021 01:00 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 31 August 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim first half-year 2021 results. Please find enclosed the report and...
PCI Biotech: Invitation to first half-year 2021 result presentation
August 23, 2021 04:00 ET
|
PCI Biotech Holding ASA
Oslo, Norway, 23 August 2021 - PCI Biotech’s (OSE: PCIB) first half-year 2021 interim report will be released on 31 August 2021 at 07.00 CEST. The interim report and presentation will be made...
PCI Biotech: US patent for the vaccine technology (fimaVacc) in combination with checkpoint inhibitors
May 31, 2021 05:16 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 31 May 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces that the U.S. Patent and Trademark Office (USPTO) has informed the company that a new...
PCI Biotech receives Orphan Drug Designation in South Korea for fimaporfin in the treatment of bile duct cancer
May 28, 2021 08:51 ET
|
PCI Biotech Holding ASA
Oslo, 28 May 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that the Ministry of Food and Drug Safety (MFDS) in South Korea has granted Orphan Drug...
PCI Biotech Minutes from Annual General Meeting 2021
May 28, 2021 05:24 ET
|
PCI Biotech Holding ASA
Oslo, 28 May 2021. The Annual General Meeting in PCI Biotech Holding ASA took place today, 28 May 2021. All proposals were resolved by the Annual General Meeting as presented in the notice convening...